Suppr超能文献

在唐氏综合征小鼠模型中,SARS-CoV-2感染导致疾病严重程度和死亡率增加。

SARS-CoV-2 Infection Causes Heightened Disease Severity and Mortality in a Mouse Model of Down Syndrome.

作者信息

Pechous Roger D, Malaviarachchi Priyangi A, Xing Zhuo, Douglas Avrium, Crane Samantha D, Theriot Hayley M, Zhang Zijing, Ghaffarieh Alireza, Huang Lu, Yu Y Eugene, Zhang Xuming

机构信息

Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

The Children's Guild Foundation Down Syndrome Research Program, Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

出版信息

Biomedicines. 2024 Feb 28;12(3):543. doi: 10.3390/biomedicines12030543.

Abstract

Recent epidemiological studies suggest that individuals with Down syndrome are more susceptible to SARS-CoV-2 infection and have higher rates of hospitalization and mortality than the general population. However, the main drivers behind these disparate health outcomes remain unknown. Herein, we performed experimental infections with SARS-CoV-2 in a well-established mouse model of Down syndrome. We observed similar SARS-CoV-2 replication kinetics and dissemination in the primary and secondary organs between mice with and without Down syndrome, suggesting that both groups have similar susceptibilities to SARS-CoV-2 infection. However, Down syndrome mice exhibited more severe disease as defined by clinical features including symptoms, weight loss, pulmonary function, and survival of mice. We found that increased disease severity in Down syndrome mice could not be attributed solely to increased infectivity or a more dramatic pro-inflammatory response to infection. Rather, results from RNA sequencing suggested that differences in the expression of genes from other physiological pathways, such as deficient oxidative phosphorylation, cardiopulmonary dysfunction, and deficient mucociliary clearance in the lungs may also contribute to heightened disease severity and mortality in Down syndrome mice following SARS-CoV-2 infection.

摘要

近期的流行病学研究表明,唐氏综合征患者比普通人群更容易感染新冠病毒,且住院率和死亡率更高。然而,这些不同健康结果背后的主要驱动因素仍不明确。在此,我们在一个成熟的唐氏综合征小鼠模型中进行了新冠病毒的实验性感染。我们观察到,有无唐氏综合征的小鼠在主要和次要器官中的新冠病毒复制动力学和传播情况相似,这表明两组对新冠病毒感染的易感性相似。然而,根据包括症状、体重减轻、肺功能和小鼠存活率等临床特征来定义,唐氏综合征小鼠表现出更严重的疾病。我们发现,唐氏综合征小鼠疾病严重程度增加不能仅仅归因于感染性增加或对感染更剧烈的促炎反应。相反,RNA测序结果表明,其他生理途径中基因表达的差异,如氧化磷酸化缺陷、心肺功能障碍以及肺部黏液纤毛清除功能缺陷,也可能导致唐氏综合征小鼠在感染新冠病毒后疾病严重程度和死亡率升高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d57b/10967796/7727359a927b/biomedicines-12-00543-g001.jpg

相似文献

1
SARS-CoV-2 Infection Causes Heightened Disease Severity and Mortality in a Mouse Model of Down Syndrome.
Biomedicines. 2024 Feb 28;12(3):543. doi: 10.3390/biomedicines12030543.
2
SARS-CoV-2 superinfection in CD14 monocytes with latent human cytomegalovirus (HCMV) promotes inflammatory cascade.
Virus Res. 2024 Jul;345:199375. doi: 10.1016/j.virusres.2024.199375. Epub 2024 Apr 22.
3
Infiltrating monocytes drive cardiac dysfunction in a cardiomyocyte-restricted mouse model of SARS-CoV-2 infection.
J Virol. 2024 Sep 17;98(9):e0117924. doi: 10.1128/jvi.01179-24. Epub 2024 Aug 29.
6
SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
J Virol. 2022 Jan 12;96(1):e0151121. doi: 10.1128/JVI.01511-21. Epub 2021 Oct 20.
8
Endothelial cell infection and dysfunction, immune activation in severe COVID-19.
Theranostics. 2021 Jul 6;11(16):8076-8091. doi: 10.7150/thno.61810. eCollection 2021.
9
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
mBio. 2021 Aug 31;12(4):e0097021. doi: 10.1128/mBio.00970-21. Epub 2021 Aug 3.

本文引用的文献

1
DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner.
PLoS Biol. 2023 Jun 13;21(6):e3002097. doi: 10.1371/journal.pbio.3002097. eCollection 2023 Jun.
2
Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model.
Nat Genet. 2023 Jun;55(6):1034-1047. doi: 10.1038/s41588-023-01399-7. Epub 2023 Jun 5.
3
Excessive negative regulation of type I interferon disrupts viral control in individuals with Down syndrome.
Immunity. 2022 Nov 8;55(11):2074-2084.e5. doi: 10.1016/j.immuni.2022.09.007. Epub 2022 Oct 14.
4
Prevalence of Infectious Diseases Among 6078 Individuals With Down Syndrome in the United States.
J Patient Cent Res Rev. 2022 Jan 17;9(1):64-69. doi: 10.17294/2330-0698.1876. eCollection 2022 Winter.
5
Human genetic and immunological determinants of critical COVID-19 pneumonia.
Nature. 2022 Mar;603(7902):587-598. doi: 10.1038/s41586-022-04447-0. Epub 2022 Jan 28.
6
clusterProfiler 4.0: A universal enrichment tool for interpreting omics data.
Innovation (Camb). 2021 Jul 1;2(3):100141. doi: 10.1016/j.xinn.2021.100141. eCollection 2021 Aug 28.
7
Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome.
Front Aging Neurosci. 2021 Jul 1;13:700280. doi: 10.3389/fnagi.2021.700280. eCollection 2021.
8
Down syndrome and type I interferon: not so simple.
Curr Opin Immunol. 2021 Oct;72:196-205. doi: 10.1016/j.coi.2021.06.006. Epub 2021 Jun 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验